lisinopril actavis 10 mg tablett
actavis group ptc ehf. - lisinoprildihydrat - tablett - 10 mg - lisinoprildihydrat 10,86 mg aktiv substans; mannitol hjälpämne - lisinopril
lisinopril stada 20 mg tablett
stada arzneimittel ag - lisinoprildihydrat - tablett - 20 mg - lisinoprildihydrat 21,78 mg aktiv substans; mannitol hjälpämne - lisinopril
lisinopril actavis 20 mg tablett
actavis group ptc ehf. - lisinoprildihydrat - tablett - 20 mg - lisinoprildihydrat 21,72 mg aktiv substans; mannitol hjälpämne - lisinopril
lisinopril actavis 5 mg tablett
actavis group ptc ehf. - lisinoprildihydrat - tablett - 5 mg - lisinoprildihydrat 5,43 mg aktiv substans; mannitol hjälpämne - lisinopril
lisinopril stada 10 mg tablett
stada arzneimittel ag - lisinoprildihydrat - tablett - 10 mg - mannitol hjälpämne; lisinoprildihydrat 10,89 mg aktiv substans - lisinopril
lisinopril stada 5 mg tablett
stada arzneimittel ag - lisinoprildihydrat - tablett - 5 mg - mannitol hjälpämne; lisinoprildihydrat 5,445 mg aktiv substans - lisinopril
lisinopril arrow 2,5 mg tablett
arrow generics ltd - lisinoprildihydrat - tablett - 2,5 mg - lisinoprildihydrat 2,723 mg aktiv substans; mannitol hjälpämne - lisinopril
lisinopril arrow 20 mg tablett
arrow generics ltd - lisinoprildihydrat - tablett - 20 mg - lisinoprildihydrat 21,78 mg aktiv substans; mannitol hjälpämne - lisinopril
lisinopril arrow 5 mg tablett
arrow generics ltd - lisinoprildihydrat - tablett - 5 mg - lisinoprildihydrat 5,445 mg aktiv substans; mannitol hjälpämne - lisinopril
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.